ABREVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ABREVA (ABREVA).
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
| Metabolism | Docosanol is applied topically with minimal systemic absorption. No significant metabolism occurs. No active metabolites. |
| Excretion | Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes. |
| Half-life | Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use. |
| Protein binding | Renally negligible; not extensively studied. For the absorbed fraction, protein binding is presumed to be high (>99%) due to the lipophilic nature of docosanol, binding primarily to albumin and lipoproteins. |
| Volume of Distribution | Systemic absorption is minimal; thus Vd is not clinically relevant. Based on animal studies, Vd is estimated to be approximately 1.5 L/kg, reflecting distribution into total body water and lipid compartments. |
| Bioavailability | Topical administration: bioavailability is less than 1% due to minimal percutaneous absorption; systemic exposure is negligible. Not administered via other routes. |
| Onset of Action | Topical application: clinical effect (reduction of cold sore healing time) is observed as early as 24 hours after initiation of treatment, with time to healing significantly reduced by day 2-3. |
| Duration of Action | Topical application applied five times daily until healed; the duration of action is the interval between doses, which supports five-times-daily application. The therapeutic effect persists throughout the treatment course (typically 4-7 days). |
| Molecular Weight | 326.56 |
Apply a thin layer to the affected area 5 times daily for 4 days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | Approved for use in patients aged 12 years and older: apply a thin layer 5 times daily for 4 days. |
| Geriatric use | No specific dosage adjustment required; use same as adult dosing. |
| 1st trimester | No adequate studies in pregnant women. Animal studies have not shown fetal harm. Use only if clearly needed. |
| 2nd trimester | No adequate studies in pregnant women. Animal studies have not shown fetal harm. Use only if clearly needed. |
| 3rd trimester | No adequate studies in pregnant women. Animal studies have not shown fetal harm. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for ABREVA (ABREVA).
| Placental transfer | Unknown if docosanol crosses the placenta. Molecular weight (approximately 326 Da) suggests possible transfer. |
| Breastfeeding | Not known if docosanol is excreted in breast milk. Caution advised due to potential for adverse effects in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to docosanol or any component of the formulation
| Precautions | Not for ophthalmic, intranasal, intravaginal, or intraoral use., Avoid application to mucous membranes., Immunocompromised patients: consider alternative therapy for severe infections., Local irritation or allergic contact dermatitis may occur. |
| Food/Dietary | No known food interactions. Avoid acidic or spicy foods if they irritate the lesion. Maintain good hydration and nutrition to support immune function. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits may warrant use. No first trimester-specific risks identified. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in animal studies. |
| Apply at first prodromal symptoms (tingling, burning) for maximal efficacy. Avoid application to mucous membranes or inside the nose/mouth. Use a fingertip to apply a thin layer to the lesion; do not share the tube. Lesions should be kept clean and dry; avoid coverings unless instructed. Consider combination therapy with oral antivirals for frequent or severe outbreaks. |
| Patient Advice | Start applying at the first sign of a cold sore (tingling, itching, or redness). · Wash hands before and after application to prevent spreading the virus. · Apply a small amount (pea-sized) to the affected area, typically 5 times a day until healed. · Do not use on broken skin or mucous membranes (inside mouth, eyes, or genital area). · Avoid kissing or sharing utensils, towels, or lip products while the sore is present. · The tube is for single-patient use only; do not share with others. · May cause mild stinging or redness; if severe irritation occurs, discontinue use. · See a doctor if the sore is severe, lasts longer than 10 days, or you have frequent outbreaks. |